Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 4,980 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Gout, Chronic Kidney Diseases
Interventions: allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped), Placebo, vehicle control (allopurinol-shaped); Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 23
States / cities: Loma Linda, California • San Diego, California • San Francisco, California + 19 more

Conditions: Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8
Interventions: Atezolizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Quality-of-Life Assessment; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1026
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 683 more

Conditions: Diabetes
Interventions: Blood Glucose meter; Other
Lead sponsor: Ascensia Diabetes Care; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: San Diego, California • Tampa, Florida

Conditions: Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions: Lenalidomide, Placebo; Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 13
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 9 more

Conditions: Breast Cancer
Interventions: anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1454
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more

Conditions: Bowel Preparation
Interventions: CLENPIQ, MIRALAX, SENNA; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 12 Months to 8 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Mobile, Alabama • San Diego, California • Baltimore, Maryland

Conditions: Head and Neck Cancer, Liver Cancer, Breast Cancer, Gastric Cancer, Non-Small Cell Lung Cancer
Interventions: CUDC-101; Drug
Lead sponsor: Curis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • Wheat Ridge, Colorado + 4 more

Conditions: Brain Injuries
Interventions: MRI Scans; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 0 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 18
States / cities: Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 15 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 19
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 15 more

Conditions: Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Patient Observation, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 284
States / cities: Jonesboro, Arkansas • Beverly Hills, California • Dublin, California + 226 more

Conditions: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Unclassified Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radium Ra 223 Dichloride; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 37 more

Conditions: EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Bevacizumab, Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 19
States / cities: La Jolla, California • Decatur, Illinois • Peoria, Illinois + 16 more

Conditions: Cystic Fibrosis
Interventions: Not listed
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more

Conditions: Colorectal Adenoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 937 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2020
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland • Portsmouth, Virginia

Conditions: Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Interventions: Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis, Idarubicin, Mercaptopurine, Methotrexate, Mitoxantrone Hydrochloride, Tretinoin; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 21 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 112
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 87 more

Conditions: Medulloblastoma
Interventions: Cisplatin, Craniospinal Irradiation, Cyclophosphamide, Involved-Field Radiation Therapy, Laboratory Biomarker Analysis, Lomustine, Quality-of-Life Assessment, Radiation Therapy, Vincristine Sulfate; Drug · Radiation · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2024
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 132 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: HCD122; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: La Jolla, California • Beech Grove, Indiana • Baltimore, Maryland + 2 more

Conditions: HIV Infections, Osteopenia, Osteoporosis
Interventions: Zoledronate, Zoledronate placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hepatitis C
Interventions: Integrated care model, Usual Care Model; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 3
States / cities: Palo Alto, California • San Diego, California • The Bronx, New York

Conditions: Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
Interventions: Durvalumab, Standard Chemotherapy, Ipilimumab and Nivolumab; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: La Jolla, California • Miami, Florida • Tampa, Florida + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: RO6889450, Placebo, Risperidone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 287 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 24
States / cities: Little Rock, Arkansas • Bellflower, California • Culver City, California + 20 more

Conditions: Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
Interventions: Orbital Atherectomy, Balloon; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,005 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 104
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 83 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Pemziviptadil (PB1046); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 26
States / cities: Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more

Conditions: Covid19
Interventions: Hyperbaric oxygen therapy; Combination Product
Lead sponsor: Peter Lindholm; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: La Jolla, California

Search by objective public record fields.

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Blood Glucose Testing and You

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Study Assessing CLENPIQ as Bowel Preparation for Pediatric Colonoscopy

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

MRI Markers of Outcome After Severe Pediatric TBI

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations

A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

Colorectal Neoplasia Screening w Colonoscopy in Asymptomatic Women at Regional Navy/Army Medical Ctrs: The CONCeRN Trial

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Bisphosphonate Therapy for HIV-Infected Adults With Decreased Bone Mineral Density

An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial

Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH

Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela